期刊文献+

Caspase8及caspase3单核苷酸多态性与晚期非小细胞肺癌铂类化疗敏感性的相关性 被引量:1

下载PDF
导出
摘要 目的探讨caspase8和caspase3单核苷酸多态性与晚期非小细胞肺癌(NSCLC)铂类化疗敏感性的关系。方法利用PCR-RELP技术进行单核苷酸多态性(SNP)基因分型检测。对患者近期及远期疗效进行随访。结果 caspase8 rs3769818、rs3834129、caspase3 rs4647693存在SNP。caspase3 rs4647693 SNP与近期疗效有关,A/A基因型铂类化疗有效率高于A/G及G/G基因型。caspase8 rs3769818、rs3834129SNP与顺铂近期疗效无显著差异(P>0.05)。rs3769818、rs4647693 SNP在无进展生存期中均体现出显著差异,且其与疾病的分期共同影响无进展生存期,而rs3834129SNP在无进展生存期中无显著差异。结论 caspase8 rs3769818、caspase3 rs4647693 SNP可能是晚期NSCLC铂类化疗敏感性的潜在预测因子。
作者 阎瑾 哈敏文
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第13期3556-3559,共4页 Chinese Journal of Gerontology
基金 辽宁省科技厅科研项目(No.2012225019)
  • 相关文献

参考文献6

  • 1赵静,张文,李文桦,张哲,朱丹,余绮荷,郭伟剑,李进.MTHFR和ABCG2单核苷酸多态性对晚期结直肠癌一线化疗疗效的预测作用[J].肿瘤,2012,32(9):709-716. 被引量:8
  • 2倪勤,刘冰,金明娟,马新源,姚开颜,李其龙,陈坤.CASP3基因多态及单体型分布与乳腺癌危险性的关联研究[J].浙江大学学报(医学版),2011,40(3):259-264. 被引量:9
  • 3Jin SungJang,Kyung MeeKim,Jin EunChoi,Sung IckCha,Chang HoKim,Won KeeLee,SinKam,Tae HoonJung,Jae YongPark.Identification of polymorphisms in the Caspase‐3 gene and their association with lung cancer risk[J].Mol Carcinog.2008(5)
  • 4David J. Stewart.Mechanisms of resistance to cisplatin and carboplatin[J].Critical Reviews in Oncology and Hematology.2007(1)
  • 5Ji-Woong Son,Hyo-Kyung Kang,Myung Hwa Chae,Jin Eun Choi,Jung Min Park,Won Kee Lee,Chang Ho Kim,Dong Sun Kim,Sin Kam,Young Mo Kang,Jae Yong Park.Polymorphisms in the caspase-8 gene and the risk of lung cancer[J].Cancer Genetics and Cytogenetics.2006(2)
  • 6Hong Sug Kim,Jong Woo Lee,Young Hwa Soung,Won Sang Park,Su Young Kim,Jong Heun Lee,Jik Young Park,Youg Gu Cho,Chang Jae Kim,Seong Whan Jeong,Suk Woo Nam,Sang Ho Kim,Jung Young Lee,Nam Jin Yoo,Sug Hyung Lee.Inactivating mutations of caspase-8 gene in colorectal carcinomas[J].Gastroenterology.2003(3)

二级参考文献42

  • 1王家祥,郑树.Caspase-3 and survivin expression in pediatric neuroblastoma and their roles in apoptosis[J].Chinese Medical Journal,2004,17(12):1821-1824. 被引量:39
  • 2JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J CUn, 201 1, 61(2):69-90.
  • 3TOURNIGAND C, ANDRE T, ACHILLE E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized CERCOR study[J].JClin Oncol, 2004, 22(2):229-237.
  • 4COLUCCI G, GEBBIA V, PAOLETTI G,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Cruppo Oncologico Dell,Italia Meridionale[J].J Clin Oncol, 2005, 23(22):4866-4875.
  • 5DUCREUX M, BENNOUNA J, HEBBAR M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128(3):682-690.
  • 6ENCSTROM P F, ARNOLETTI J P,BENSON A R, et aL NCCN Clinical Practice Guidelines in Oncology: colon cancer[J]. J Natl Compr Cane Neter 2009, 7(8):778-831.
  • 7Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. AdvancedColorectal Cancer Meta-Analysis Project[J].J ClinOncol, 1992, 10(6):896-903.
  • 8VAN CUTSEM E, HOFF P M,HARPER P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials[J].BrJ Cancer, 2004, 90(6):11 90-1197.
  • 9HOFF P M,ANSARI R,BATIST G, ef al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study[J].J Clin Oncol, 2001,19(8):2282-2292.
  • 10DOROSHOW J H, MULTHAUF P, LEONG L,et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy[J]. J Clin Oncol, 1 990, 8(3):491-501.

共引文献15

同被引文献11

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部